Carnegie Capital Asset Management LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,550 shares of the biopharmaceutical company's stock after buying an additional 187 shares during the quarter. Carnegie Capital Asset Management LLC's holdings in Bristol-Myers Squibb were worth $7,882,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BMY. Dakota Wealth Management acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $332,000. Covestor Ltd raised its holdings in shares of Bristol-Myers Squibb by 111.5% in the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 1,082 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 53.2% in the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company's stock valued at $12,075,000 after purchasing an additional 57,444 shares in the last quarter. Ergoteles LLC acquired a new stake in Bristol-Myers Squibb during the 1st quarter worth $1,997,000. Finally, Mackenzie Financial Corp raised its stake in Bristol-Myers Squibb by 25.1% during the 1st quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company's stock worth $24,725,000 after acquiring an additional 68,018 shares in the last quarter. 75.51% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Up 1.1 %

Shares of NYSE BMY traded up $0.78 during trading hours on Friday, reaching $68.98. The stock had a trading volume of 3,850,653 shares, compared to its average volume of 8,100,103. The business's fifty day moving average price is $70.16 and its two-hundred day moving average price is $72.82. The company has a current ratio of 1.25, a quick ratio of 1.14 and a debt-to-equity ratio of 1.13. The firm has a market cap of $145.09 billion, a price-to-earnings ratio of 23.12, a P/E/G ratio of 1.48 and a beta of 0.46. Bristol-Myers Squibb has a 52-week low of $65.28 and a 52-week high of $81.43.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last released its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. The business had revenue of $11.41 billion during the quarter, compared to analyst estimates of $11.20 billion. During the same quarter last year, the business posted $1.83 EPS. The company's revenue was down 4.8% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post 8.06 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date is Thursday, April 6th. Bristol-Myers Squibb's payout ratio is 77.29%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Atlantic Securities lifted their target price on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, February 3rd. Jefferies Financial Group started coverage on shares of Bristol-Myers Squibb in a research report on Monday, March 6th. They set a "hold" rating and a $62.00 target price for the company. StockNews.com started coverage on shares of Bristol-Myers Squibb in a research report on Thursday, March 16th. They issued a "strong-buy" rating for the company. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 3rd. Finally, Cantor Fitzgerald began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, January 17th. They issued an "overweight" rating and a $95.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $79.69.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 240,000 shares of the company's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the transaction, the chief executive officer now owns 236,104 shares in the company, valued at $17,625,163.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Ann Powell sold 11,183 shares of the business's stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the completion of the sale, the executive vice president now owns 23,043 shares of the company's stock, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Giovanni Caforio sold 240,000 shares of the business's stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the transaction, the chief executive officer now directly owns 236,104 shares of the company's stock, valued at $17,625,163.60. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Featured Articles

• Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
• What is a Gold IRA, and is it a Viable Investment?
• Is Braze, Inc Ready To Rocket Higher?
• Mullen Automotive Makes Deliveries; Short-Squeeze Possible
• Can Frontline Maintain This Momentum?
• Walmart Shares Jump on Evercore Analyst Upgrade

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.